Navigation Links
Bioheart, Inc. to Transfer to Nasdaq Capital Market
Date:6/10/2008

SUNRISE, Fla., June 10 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) today announced that it has received approval to transfer the listing of its common stock to the Nasdaq Capital Market. The Company's common stock will be transferred from The Nasdaq Global Market to The Nasdaq Capital Market at the opening of business on Wednesday, June 11, 2008. The Nasdaq Capital Market is a tier of the Nasdaq Stock Market for companies with a lower market capitalization requirement than the Global Market tier. The Company's stock will continue to trade, and benefit from the liquidity provided by the Nasdaq Stock Market.

The listing transfer is in response to a letter dated May 21, 2008 from the Nasdaq Stock Market, Inc. which, as previously announced, notified the Company that it was not in compliance with certain of the continued listing requirements for the Nasdaq Global Market.

Bioheart's trading symbol on The Nasdaq Capital Market will remain 'BHRT.'

About Bioheart, Inc.:

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic proteins.

(MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.)


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
2. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
3. Bioheart, Inc. Announces Financial Results for First Quarter 2008
4. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
5. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
9. Biological electron transfer captured in real time
10. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
11. Easily Lift, Transfer and Reposition Patients with Ground-Breaking Liftaem(TM) System from Smart Medical Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):